供者与第三方巨细胞病毒特异性细胞毒性T淋巴细胞过继治疗异基因造血干细胞移植后难治性巨细胞病毒DNA血症和疾病
该单中心回顾性研究纳入2017年1月至2021年9月接受CMV-CTL治疗的53例allo-HSCT后难治性CMV DNA血症或疾病成人患者,供者组40例、第三方组13例;治疗6周内两组完全缓解率分别为65.0%和69.2%(p=1.000),2年总生存率分别为59.6%和53.8%(p=0.860),作者认为供者与第三方CMV-CTL疗效和安全性相当。
要点
- 供者组与第三方组治疗6周内完全缓解率分别为65.0%和69.2%,p=1.000。
- 供者组与第三方组2年总生存率分别为59.6%和53.8%,p=0.860。
- 输注后3个月内急性GVHD发生率供者组10.0%、第三方组15.4%。
核心结论
- 作者认为供者与第三方CMV-CTL对难治性CMV DNA血症和疾病具有相当的疗效和安全性。
研究设计与样本
- 单中心回顾性研究,比较2017年1月至2021年9月本中心allo-HSCT后难治性CMV DNA血症或疾病患者接受供者与第三方CMV-CTL的疗效和安全性。
- 共纳入53例接受CMV-CTL治疗的成人患者(年龄18岁及以上),供者组40例、第三方组13例。
主要发现
- 治疗6周内,供者组26例(65.0%)与第三方组9例(69.2%)达到完全缓解(p=1.000)。
- 2年总生存率供者组为59.6%(95%CI 46.1%-77.1%),第三方组为53.8%(95%CI 32.6%-89.1%)(p=0.860)。
- CMV-CTL输注后3个月内,供者组4例(10.0%)与第三方组2例(15.4%)发生急性移植物抗宿主病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytomegalovirus (CMV) DNAemia and disease are common complications in patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). Few studies have compared the efficacy and safety of the HSCT donor and third-party CMV-specific cytotoxic T lymphocytes (CMV-CTLs) in the treatment of CMV DNAemia and disease. In this study, we retrospectively compared the efficacy and safety of HSCT donor and third-party CMV-CTLs in patients with refractory CMV DNAemia or disease after allo-HSCT at our centre from January 2017 to September 2021. Fifty-three patients who received CMV-CTL therapy were enrolled, including 40 in the donor group and 13 in the third-party group, and they were adults aged 18 years or older. Within 6 weeks of treatment, 26 (65.0%) and 9 (69.2%) patients achieved complete response in the donor and third-party groups (p = 1.000). The 2-year overall survival was 59.6% (95% CI 46.1%-77.1%) and 53.8% (32.6%-89.1%) in the donor and third-party groups (p = 0.860). Four (10.0%) patients in the donor group and two (15.4%) patients in the third-party group developed acute graft-versus-host disease within 3 months after CMV-CTL infusions. In conclusion, our data suggest that donor and third-party CMV-CTLs have comparable efficacy and safety for refractory CMV DNAemia and disease.
引用
- Jiang Z, Fan Z, Zhang T, et al. Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024. PMID: 38168845. doi:10.1111/bjh.19282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。